Business
Launch of OptiMAL platform
Fusion Antibodies plc has officially launched its OptiMAL® platform for discovering novel human antibodies, incorporating a proprietary synthetic library and Mammalian Display technology, with the library and its design method protected by US patent no. US12378696 and pending international patents. This launch, presented at the Antibody Engineering and Therapeutics conference, signifies a key development for the company's pre-clinical antibody discovery and engineering services, aiming to accelerate the delivery of therapeutic antibodies to market. Disclaimer*
About this update from Fusion Antibodies Plc
[{"type":"text","content":"\n\n16 December 2025\n \nFusion Antibodies plc\n(\"Fusion\" or the \"Company\")\n \nLaunch of the OptiMAL® Human Antibody Discovery platform\n \nFusion Antibodies plc (AIM: FAB), specialists in pre-clinical antibody discovery, engineering and supply for both therapeutic drug and diagnostic applications, announces the official launch of the OptiMAL® platform for the discovery of novel human antibodies. The OptiMAL® platform incorporates the Company's naïve, synthetic library of antibody sequences and the Mammalian Display used to select individual antibodies from the Library against a target of interest. As has been previously announced by the Company, the OptiMAL® library and the method for designing the Library are protected under US patent no. US12378696 and patents pending in other territories.\n \nThe official launch of the OptiMAL® platform took place at the Antibody Engineering and Therapeutics conference in San Diego with a speaker presentation by Dr. Richard Buick, CSO, followed by poster presentations and an exhibit booth. CEO Adrian Kinkaid also attended the official launch of OptiMAL®.\n \nRichard Buick, CSO of Fusion, said: \"I am delighted to see the culmination of several years' work presented to an audience of antibody industry peers and look forward to the future of using this technology to bring more human therapeutic antibodies to the market.\"\n \nEnquiries: \n \n\n\n\n\nInvestor questions on this announcement\n\n\n\n\n\n\n\n\nWe encourage all investors to share questions on this announcement via our investor hub\n\n\nInvestor hub\n\n\n\n\n \n\n\n\n\n\n\n\n\nFusion Antibodies plc\n\n\nwww.fusionantibodies.com\n\n\n\n\nAdrian Kinkaid, Chief Executive Officer\nStephen Smyth, Chief Financial Officer\n\n\nVia Walbrook PR\n\n\n\n\n \n\n\n\n\n\n\n\n\nAllenby Capital Limited\n\n\nTel: +44 (0) 20 3328 5656 \n\n\n\n\nJames Reeve/Vivek Bhardwaj (Corporate Finance)\nTony Quirke/Joscelin Pinnington (Sales and Corporate Broking)\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \n\n\n\n\n\n\n\n\nShard Capital Partners LLP\n\n\n\n\n\n\n\n\nDamon Heath (Joint Broker)\n\n\nTel: +44 (0) 207 186 9952\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \n\n\n\n\n\n\n\n\nWalbrook PR\n\n\nTel: +44 (0)20 7933 8780 or [email protected]\n\n\n\n\nAnna Dunphy\n\n\nMob: +44 (0)7876 741 0...